



**Euro Forums**

## **Retina Forum**

Weds. 04 Oct.

**Hyatt Regency Hotel  
Amsterdam**

follow us on



@OphthalmologyFF #OFF2023

## **Retina Programme**



# We Help People See Brilliantly.

At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated portfolio of contact lenses, lens care solutions, and pharmaceutical and over-the-counter eye drops. Alcon is also at the forefront of innovation, partnering with Eye Care Professionals to bring the gift of sight to more people around the world.

That's been our legacy for more than 75 years—and continues to guide our focus towards the brilliant future ahead.

Learn more at [alcon.com](https://alcon.com)

## CONNECT WITH US!



@AlconEyeCare  
@AlconCareers



@Alcon



@AlconLife



@Alcon



# Welcome:

# RETINA FORUM 2023

## Welcome to Ophthalmology Futures 2023

We are delighted to welcome you to our Annual Ophthalmology Futures Retina Forum to be held, for the second time, in Amsterdam. Now in our 12<sup>th</sup> year of highlighting retina innovation, the 2023 Forum will showcase 21 companies developing back of the eye medical products to address unmet patient needs. As in prior years, this in-person event will bring together leading innovators, practitioners, corporate leaders and investors.

One of our fundamental goals is to make each Ophthalmology Futures meeting unique, evaluating the landscape of existing platforms as well as exploring novel developments. The past year has seen the emergence of breakthrough therapeutic options for Geographic Atrophy and a continued amplification of artificial intelligence in all phases of innovation, two topics which will be highlighted at OF 2023.

Panel topics include dual mechanism Anti-VEGF therapies, gene therapy, novel drug delivery and surgical instrumentation. As in prior years, we will address investment and regulatory trends in the retina ecosystem. We are confident that you will enjoy the

formal program as well as the networking opportunities that come with an in-person event. In recognizing that the world has forever changed with regard to travel as a result of a global pandemic, our program will also have a virtual component available to those who are unable to make the trip to Amsterdam.

Ophthalmology Futures Forums would like to thank our key advisors, particularly Professors Adnan Tufail and Ursula Schmidt-Erfurth who, for many years, have helped us shape the Forum program. We would also like to thank our corporate presenters and distinguished faculty for joining us, as well as our generous sponsors who allow us to maintain modest registration fees for all attendees!

Thank you for attending Ophthalmology Futures Retina Forum 2023 in Amsterdam.

**Keith Barton & Kuldev Singh**

on behalf of the Ophthalmology Futures Team



Vision Futures Limited, London, UK.  
Registered in England No: 8125858.




# Helping Doctors Improve Their Patients' Quality of Life.

ZEISS Medical Technology Business Group



Seeing beyond



## Improving Quality of Life

ZEISS Medical Technology is proud to support the **Ophthalmology Futures Retina Forum**.

[www.zeiss.com](http://www.zeiss.com)

# Stellest®

Essilor®  
#1 in spectacle lenses  
worldwide\*

EssilorLuxottica is proud to  
support the **Ophthalmology  
Futures Forums 2023**.



\*Euromonitor, Eyewear 2023 edition; Essilor International company; worldwide retail value sales at RSP.  
[www.essilorluxottica.com](http://www.essilorluxottica.com)

In the relentless pursuit of  
treatments for retinal diseases,

# APELLIS IS LIGHTING THE WAY FORWARD

Our journey starts with  
geographic atrophy (GA)

GA is an advanced form of age-related macular degeneration that leads to progressive and irreversible vision loss, substantially impacting patient quality of life.<sup>1-3</sup>

It represents the most significant unmet medical need in ophthalmology given there are currently no approved treatments available.<sup>4</sup>

OUR SEARCH FOR SOLUTIONS  
KNOWS NO LIMITS BECAUSE THESE  
PATIENTS DESERVE NOTHING LESS

Visit **apellis-amd.eu** to learn  
more about Apellis and our journey  
in geographic atrophy



Apellis

**References:** 1. Gehrs KM, et al. *Ann Med* 2006;38(7):450–471. 2. Fleckenstein M, et al. *Ophthalmology* 2018;125(3):369–390. 3. Patel PJ, et al. *Clin Ophthalmol* 2020;14:15–28. 4. Riquet D (n.d.). European Parliament. Available at: [https://www.europarl.europa.eu/doceo/document/P-9-2022-000876\\_EN.html](https://www.europarl.europa.eu/doceo/document/P-9-2022-000876_EN.html) (accessed January 2023).

# Speakers:

## PANELLISTS & CHAIRS

## PRESENTING COMPANIES

### CHAIRS & PANELLISTS

#### B

- **Francesco Bandello**  
Professor, University Vita-Salute
- **Keith Barton**  
Co-chair, Ophthalmology Futures
- **Caroline Bauml**  
CMO, Apellis Pharmaceuticals
- **Francine Behar-Cohen**  
Scientific Founder, EyeVensys
- **Christopher Brittain**  
Global Head of Ophthalmology Development, Genentech

#### C

- **Usha Chakravarthy**  
Professor of Ophthalmology & Vision Science, Queens' University of Belfast
- **Gemmy Cheung**  
Ophthalmologist, Singapore National Eye Centre
- **Victor Chong**  
Global Head of Retina, Janssen
- **Art Ciociola**  
VP Regulatory Affairs  
Ophthalmology & Medical Devices, Novartis Pharma AG
- **Andreas Clemens**  
Global Head Medical Strategy, AID & IRD, Novartis Pharma AG
- **Daniela Cuoto**  
Partner, Biogenesis Ventures

#### E

- **Jason Ehrlich**  
CEO, Ollin Biosciences

#### F

- **Dominik Fischer**  
Professor of Ophthalmology, University of Tuebingen

#### G

- **Mohamed Genead**  
Co-Founder, CEO & President, Aviceda Therapeutics

- **Andrzej Grzybowski**  
Professor, University of Warmia & Mazury
- **Robyn Guymer**  
Deputy Director, Head of Macular Research, Centre for Eye Research, Australia

#### H

- **Paul Hallen**  
VP & Global Head Alcon Retina, Alcon
- **Rafiq Hasan**  
CEO, Complement Therapeutics Ltd
- **Erin Henry**  
VP, Product, Strategy & Innovation, Iveric Bio, An Astellas Company
- **Nancy Holecamp**  
Visiting Professor, Roche-Genentech

#### J

- **Lionel Jouet**  
VP, New Products Strategy & Global Marketing, Bausch + Lomb
- **Eugene de Juan**  
Professor, ForSight Labs, LLC

#### K

- **Rusty Kelley**  
Managing Director, Foundation Fighting Blindness
- **Robert Kim**  
Senior VP, 4D Molecular Therapeutics

#### L

- **Melissa Liew**  
VP & Global Translational Medicine Head, Ophthalmology, Novartis Institutes for Biomedical Research
- **Nanna Lüneborg**  
Partner, Forbion

#### M

- **Stephanie Magazzeni**  
Head of Digital Research & Innovation, ZEISS
- **Samarendra Mohanty**  
President & CSO, Nanoscope Therapeutics, Inc.

- **Maryam Mokhtarzadeh**  
Senior Director Regulatory Strategy, REGENXBIO

#### N

- **Kester Nahen**  
CEO, Notal Vision Ltd

#### O

- **Michael O'Rourke**  
CEO, Re-Vana Therapeutics

#### P

- **Elisa Petris**  
Lead Partner, Syncona
- **Stephen Poor**  
Global Program Clinical Head, Scientific Engagement Lead  
Novartis Pharma AG

#### R

- **Karlheinz Rein**  
Senior VP Surgical Ophthalmology, Carl Zeiss Meditec AG

#### S

- **Ursula Schmidt-Erfurth**  
Professor & Chair, Medical University of Vienna
- **Grégoire Schwach**  
Head of Biologics, Re-Vana Therapeutics
- **Surendra Sharma**  
Senior VP, Outlook Therapeutics
- **Riad Sherif**  
CEO, Oculis SA
- **Dawn Sim**  
Medical Director, Genentech
- **Kuldev Singh**  
Co-chair, Ophthalmology Futures
- **Michael Singer**  
Clinical Professor, University of Texas Health Science Center
- **Sobha Sivaprasad**  
Consultant Ophthalmologist, Moorfields Eye Hospital NHS Trust
- **Marc de Smet**  
Director, Microinvasive Ocular Surgery - Retina & Inflammation

- **Paulo Stanga**  
Retina Lead Consultant  
Ophthalmologist & Vitreoretinal  
Surgeon, London Vision Clinic
- **Einar Stefánsson**  
Professor, University of Iceland
- **Klaus Stöckemann**  
Managing Partner, Peppermint  
Venture Partners GmbH

## T

- **Christina Takke**  
Co-Founder & Managing Director,  
V-Bio Ventures
- **Cynthia Toth**  
Joseph A.C. Wadsworth  
Distinguished Professor of  
Ophthalmology, Duke Health
- **Sally Tucker**  
President, Global Services, Lexitas
- **Adnan Tufail**  
Prof of Ophthalmology, Moorfields  
Eye Hospital NHS Trust

## V

- **Ramin Valian**  
VP, Allergan, an AbbVie Company

## W

- **Nadia Waheed**  
CMO, Beacon Therapeutics
- **Limin Wang**  
Regional General Manager,  
Rimonci Capital
- **Stephane Wolf**  
Global Head Digital Health  
Solutions, Ophthalmology,  
Novartis Pharma AG

## PRESENTING COMPANIES

## A

- **AAVantegarde Bio**  
Natalia Misciattelli  
Head of Corp Development
- **Aldropika Therapeutics**  
Uttam Surana  
CSO
- **Apellis Pharmaceuticals**  
Lukas Scheibler  
Chief Research Officer
- **Aviceda Therapeutics**  
Tarek Hassan  
Chief Development Officer

## B

- **Beacon Therapeutics**  
Darin Curtiss  
VP of Clinical Development

## C

- **Complement Therapeutics**  
Rafiq Hasan  
CEO

## D

- **Deepeye Medical GmbH**  
Ratko Petrovic  
CTO

## E

- **Endogena Therapeutics**  
Matthias Steger  
CEO
- **EyeCheckup**  
Rim Khazhin  
CTO
- **Eyevensys**  
Francine Behar Cohen  
CEO & President

## I

- **Iveric Bio, An Astellas Company**  
Erin Henry  
VP, Product, Strategy & Innovation

## K

- **Kuria Therapeutics**  
Keith Ward  
CEO

## N

- **Nanoscope Therapeutics, Inc.**  
Samarendra Mohanty  
President & CSO
- **Notal Vision**  
Kester Nahen  
CEO

## O

- **Oculis SA**  
Riad Sherif  
VP Strategic Marketing & BD&L
- **OcuTerra Therapeutics**  
Kerrie Brady  
CEO & President
- **Outlook Therapeutics**  
Surendra Sharma  
SVP-Medical Affairs

## P

- **Photoprotective Technologies**  
James Gallas  
Director, New Business Development

## R

- **Re-Vana Therapeutics**  
Michael O'Rourke  
CEO
- **REGENXBIO**  
Sumie Takahara  
Director, Global Product  
& Market Planning

## T

- **Tarsier Pharma**  
Daphne Haim Langford  
CEO





An Astellas Company

# Hope in sight™

We see a world where  
vision is preserved.

Pioneering transformational  
therapies for people with  
retinal diseases.



[ivericbio.com](https://ivericbio.com)





PHARMACEUTICAL COMPANIES OF

*Johnson & Johnson*

Proud to be **silver sponsors** of Ophthalmology Futures Forums 2023

# Help us make a difference

Your support helps create a  
future without sight loss.

We can't do it without you.

[moorfieldseyecharity.org.uk/support-us](https://moorfieldseyecharity.org.uk/support-us)

We are the leading charity in the UK funding research into eye conditions like glaucoma and macular degeneration, and innovations in patient care to help patients worldwide. [moorfieldseyecharity.org.uk](https://moorfieldseyecharity.org.uk)

[moorfields.eyecharity@nhs.net](mailto:moorfields.eyecharity@nhs.net)



Moorfields Eye Charity, 162 City Road, London EC1V 2PD  
Telephone: [020 7566 2565](tel:02075662565)



Moorfields  
Eye Charity

# Timings:

## RETINA FORUM

TIMINGS ARE IN CENTRAL EUROPEAN SUMMER TIME

---

**09:30 - 10:20**

Registration

---

**10:20 - 10:30**

Welcome

---

**10:30 - 11:00**

Panel 1: **Dual Mechanism Anti-VEGF Therapies vs Novel Formulations of Older Agents: Will Patients & Providers have a Preference?**

CO-CHAIRS

- Francesco Bandello
- Robyn Guymer

PANELLISTS

- Gemmy Cheung
  - Grégoire Schwach
  - Nancy Holecamp
  - Stephen Poor
  - Surendra Sharma
- 

**11:00 - 11:30**

Panel 2: **Can AI & Digital Health Accelerate the Execution or Reduce the Cost of Clinical Trials?**

CO-CHAIRS

- Adnan Tufail
- Ursula Schmidt-Erfurth

PANELLISTS

- Andrzej Grzybowski
  - Cynthia Toth
  - Dawn Sim
  - Kester Nahen
  - Stephane Wolf
  - Stephanie Magazzeni
- 

**11:30 - 12:00**

Networking Break

---

---

**12:00 - 12:30**

Panel 3: **Novel Instrumentation for Back of the Eye Diseases: Who Will Continue to Invest?**

CHAIR

- Paulo Stanga

PANELLISTS

- Eugene de Juan
  - Karlheinz Rein
  - Lionel Jouet
  - Marc de Smet
  - Paul Hallen
- 

**12:30 - 13:00**

Panel 4: **Visual Preservation in Retinal Diseases: Will Gene Therapy Make a Dent?**

CHAIR

- Dominik Fischer

PANELLISTS

- Andreas Clemens
  - Francine Behar-Cohen
  - Nadia Waheed
  - Ramin Vallian
  - Robert Kim
  - Samarendra Mohanty
  - Victor Chong
- 

**13:00 - 13:50**

Networking Lunch

---

SPONSORED BY



---

**13:50 - 15:20**

### Company Presentations 1

- Notal Vision
  - Eyecheckup
  - Deepeye Medical
  - Photoprotective Technology
  - Endogena Therapeutics
  - Beacon Therapeutics
  - Nanoscope Therapeutics
  - AAVantegarde Bio
  - Eyevensys
  - REGENXBIO
- 

**15:20 - 15:30**

### Investment Perspective

- Nanna Lüneborg
- 

**15:30 - 16:00**

### Panel 5: Investment in Back of the Eye Products: Is it Safer than Buying Cryptocurrency?

#### CHAIR

- Nanna Lüneborg

#### PANELLISTS

- Christina Takke
  - Daniela Cuoto
  - Elisa Petris
  - Klaus Stöckemann
  - Limin Wang
  - Rusty Kelley
- 

**16:00 - 16:30**

### Panel 6: Sustained Delivery for Anti-VEGF Therapy: Come & Gone, or Still in Play?

#### CHAIR

- Eugene de Juan

#### PANELLISTS

- Christopher Brittain
  - Jason Ehrlich
  - Melissa Liew
  - Michael O'Rourke
  - Michael Singer
  - Riad Sherif
- 

**16:30 - 16:50**

### Networking Break

---

---

**16:50 - 18:30**

### Company Presentations 2

- Re-Vana Therapeutics
  - Tarsier Pharma
  - Oculis
  - Aldropika Therapeutics
  - Ocuterra Therapeutics
  - Outlook Therapeutics
  - Kuria Therapeutics
  - Complement Therapeutics
  - Aviceda Therapeutics
  - Apellis Pharmaceuticals
  - Iveric Bio, An Astellas Company
- 

**18:30 - 19:00**

### Panel 7: Global Harmonization of Regulatory Processes for Drugs & Biologics: The Impact on Retinal Disease & Therapy

#### CHAIR

- Kuldev Singh

#### PANELLISTS

- Art Ciociola
  - Maryam Mokhtarzadeh
  - Sally Tucker
- 

**19:00 - 19:30**

### Panel 8: Novel Therapies for Geographic Atrophy: How do we Measure Success for Physicians, Patients & Payers?

#### CO-CHAIRS

- Einar Stefánsson
- Usha Chakravarthy

#### PANELLISTS

- Art Ciociola
  - Caroline Baumal
  - Erin Henry
  - Mohamed Genead
  - Rafiq Hasan
  - Sobha Sivaprasad
- 

**19:30 - 19:40**

### Summary

---

**19:40 - 19:45**

### Concluding Comments

---

**19:45 - 21:00**

### Reception

---



# 2023 FORUM SPONSORS

## PLATINUM



At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

At Alcon, we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world. That's been our legacy for more than 70 years – and as the new Alcon, it's what guides our focus towards the brilliant future ahead.



STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL," which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries.

To learn more about the ICL go to:  
[www.discovericl.com](http://www.discovericl.com).

## GOLD



Apellis is a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines. At Apellis, we are committed to developing transformative therapies for people living with Geographic Atrophy (GA) by regulating complement, a part of the body's immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases such as GA, where there are currently no treatment options available.



Iveric Bio, An Astellas Company, is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients' lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit [www.ivericbio.com](http://www.ivericbio.com).

# SILVER



With a special focus on ophthalmology, ophthalmic surgery and visualization systems in the field of microsurgery, ZEISS Medical Technology supports healthcare professionals in setting new standards of care with proven medical technology and broad application competence based on cutting-edge innovations.

[www.zeiss.com](http://www.zeiss.com)



At Janssen, we are translating our understanding of the biology of underlying retinal diseases to develop needed therapies that preserve and enhance vision. Janssen's clinical-stage retinal portfolio includes leading product candidates for inherited retinal diseases XLRP and achromatopsia.

Janssen is also expanding into more common eye diseases, including age-related macular degeneration, diabetic retinopathy, and diabetic macular edema.



Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About 103,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world.

Find out more at [www.novartis.com](http://www.novartis.com)

## EssilorLuxottica

EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. Formed in 2018, its mission is to help people around the world to see more and be more by addressing their evolving vision needs and personal style aspirations. The Company brings together the complementary expertise of two industry pioneers, one in advanced lens technology and the other in the craftsmanship of iconic eyewear, to set new industry standards for vision care and the consumer experience around it. Influential eyewear brands including Ray-Ban and Oakley, lens technology brands including Varilux and Transitions, and world-class retail brands including Sunglass Hut, LensCrafters, Salmoiraghi & Viganò and GrandVision are part of the EssilorLuxottica family. EssilorLuxottica has approximately 190,000 employees.

For more information, please visit [www.essilorluxottica.com](http://www.essilorluxottica.com)



REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

Our gene therapy product candidates are designed to deliver functional genes, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy has the potential to provide long-lasting effects and improved patient outcomes. We have developed a broad pipeline of gene therapy programs using our NAV<sup>®</sup> Technology Platform. We believe this platform forms a strong foundation for our current programs, and with our ongoing research and development, we expect to continue to expand the platform.

# BRONZE



ELIOS Vision, Inc. is a private medical device company focused on the commercialization of ELIOS, a proprietary excimer laser treatment for glaucoma. Our goal is to achieve a leadership position within the glaucoma treatment category with a treatment that is proven safe and effective, 'implant free' and highly adoptable by physicians. The technique is minimally invasive and can be elegantly combined with routine cataract surgery. ELIOS helps address the needs of >80Mn people worldwide affected by glaucoma. ELIOS is approved for use in EU and is currently undergoing clinical trials for use in the US.

Visit us online at [eliosvision.com](http://eliosvision.com)



Théa is the leading independent European pharmaceutical group in ophthalmology. Leader and pioneer in preservative-free treatments, Théa is the unique partner of the eye care professionals for it has constantly been innovating to provide them and their patients with answers to unmet eye care needs. Today, Théa's network includes 1,600 collaborators, and its products are available in 75 countries around the world through its 35 affiliates and partners. In 2021, Théa had global revenues of approximately \$773 million.

The independent and family-owned and run group, founded from a R&D start-up by Henri Chibret, has been chaired since 2008 by Jean-Frédéric Chibret. [www.laboratoires-thea.com/en](http://www.laboratoires-thea.com/en)



Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

[www.glaukos.com](http://www.glaukos.com)

**THANKS TO THE  
GENEROSITY OF OUR  
SPONSORS, THERE IS  
NO FEE FOR COMPANY  
PRESENTATIONS AND  
VIRTUAL REGISTRATION  
IS COMPLIMENTARY  
FOR EVERYONE**



# NEW INNOVATOR



Radiance Therapeutics, Ltd. (RadianceTx) is revolutionising the treatment of glaucoma. Intraocular pressure (IOP) reduction by filtration surgery technologies has compelling advantages over nonsurgical treatments. However, bleb management remains challenging because of the high incidence of post-operative scarring. Randomized Controlled Trials from Moorfields Eye Hospital and collaborating institutions, demonstrate that beta therapy significantly reduces postoperative scarring. RadianceTx is addressing this unmet need by developing the RTx-RBS, a next generation Beta Ophthalmic Applicator indicated for episcleral brachytherapy.



CILIATECH is developing a new class of implant to address the increasing need to treat glaucoma durably and with zero adverse effects. The company's groundbreaking concept CID (Cilio-scleral Interpositioning Daevce) is the first implant in the industry to reduce IOP without penetrating the anterior chamber or creating subconjunctival filtration. Clinical trials show IOP is reduced by 39% at 24 months (85% patients drop free, no reoperation needed) and without ECL risk.



Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to restore vision to millions of patients with our life-changing regenerative therapies. Our first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells manufactured from a single donor can treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and central corneal thickness. The Aurion Biotech team is preparing for clinical trials in the U.S. To learn more about Aurion Biotech, visit [www.aurionbiotech.com](http://www.aurionbiotech.com)



Oculus is a global biopharmaceutical company purposefully driven to save sight, improve eye care and address significant unmet medical needs with breakthrough innovations. Oculus's highly differentiated pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments. With a presence in key international markets, Oculus is poised to deliver life-changing treatments to patients worldwide. Headquartered in Lausanne, Switzerland and with operations in Europe, the U.S. and China, Oculus is led by an experienced management team with a successful track record and supported by leading international healthcare investors.



LensGen® pioneered Modular, Shape Changing IOL technology designed to mimic the natural lens and utilize the eye's focusing mechanism to activate a fluid optic that changes shape to increase range of focus while preserving optical quality.

The Juvene® Modular, Shape Changing IOL is designed to provide a full range of continuous vision from distance to near with optical quality comparable to monofocal IOLs. Juvene fills the capsule for optimization of refractive and IOL stability and mitigation of PCO. LensGen plans to initiate its IDE pivotal study in the U.S. in Q4/2023.



ViaLase, Inc. a globally-minded, venture capital-backed, clinical stage medical technology company located in Aliso Viejo, CA. ViaLase is focused on disrupting the conventional glaucoma treatment paradigm with the introduction of a truly noninvasive image-guided femtosecond laser treatment that enhances glaucoma patient care. With a leadership team that has vast experience developing, designing, manufacturing, and commercializing the first femtosecond lasers for ophthalmic surgery for refractive and cataract patients, ViaLase looks forward to bringing that expertise and innovation to glaucoma patients worldwide.



Proud to be silver sponsors of Ophthalmology Futures Forums 2023

---



**Welcome to  
the future  
of medicine**



# 2024 EURO FORUMS

## IN BARCELONA

# SAVE THE DATES

**RETINA FORUM**  
**WEDS. 04 SEPT.**

**EUROPEAN FORUM**  
**THURS. 05 SEPT.**

KEEP UP TO DATE WITH THE LATEST ANNOUNCEMENTS  
ON OUR SOCIAL CHANNELS

follow us on



@OphthalmologyFF #OFF2023



# PROGRAMME COMMITTEE

**Ike Ahmed** | Division Head, Ophthalmology, Trillium Health Partners, Toronto, Canada. Assistant Professor, University of Toronto, Canada. Clinical Assistant Professor, University of Utah, USA.

**Jorge Alio** | Professor & Chairman of Ophthalmology, Miguel Hernandez University, Alicante, President, Visium Corporation, Spain.

**Gerd Auffarth** | Professor & Chairman, Dept. of Ophthalmology, University of Heidelberg. Director, David J. Apple International Laboratory for Ocular Pathology, International Vision Correction Research Centre, Heidelberg, Germany.

**Francesco Bandello** | Full Professor & Chairman Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele of Milan, Italy.

**David Chang** | Altos Eye Physicians & Clinical Professor, University of California, San Francisco, USA.

**Steve Charles** | Founder & CEO, Charles Retina Institute Clinical Professor of Ophthalmology, University of Tennessee, USA.

**Paul Chew** | Professor of Ophthalmology, National University of Singapore, Singapore.

**Jost Jonas** | Professor of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Germany.

**Sir Peng Khaw** | Professor of Glaucoma & Ocular Healing, Director National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital & UCL Institute of Ophthalmology, London, UK.

**Shigeru Kinoshita** | Professor & Chair, Department of Ophthalmology, Kyoto Prefectural University of Medicine, Japan.

**Richard Lindstrom** | Founder & Attending Surgeon: Minnesota Eye Consultants, Minneapolis, USA. Adjunct Professor Emeritus: University of Minnesota, USA.

**Boris Malyugin** | Chief of Department of Cataract & Implant Surgery, Deputy Director General, S. Fyodorov Eye Microsurgery Complex State Institution, Moscow, Russia.

**Prof David Spalton** | Past-president, European Society of Cataract & Refractive Surgeons London, UK.

**Prof Dr Ingeborg Stalmans** | Head of the Glaucoma Clinic, University Hospitals UZ Leuven, Belgium. Head, Ophthalmology Research Group, University KU Leuven, Belgium.

**Paulo Eduardo Stanga** | London Vision Clinic Retina Lead Consultant Ophthalmologist & Vitreoretinal Surgeon. Professor of Ophthalmology & Retinal Regeneration, University of Manchester, UK.

**José-Alain Sahel** | Endowed Professor & Chairman, Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, USA. Professor of Ophthalmology, Sorbonne Université. Chairman Departments of Ophthalmology, Quinze-Vingts National Ophthalmology Hospital & Rothschild Ophthalmology Foundation, Paris. Director, Institut de la Vision (Sorbonne Université, Inserm, CNRS, Paris).

**Ursula Schmidt-Erfurth** | Professor & Chair, Medical University of Vienna, Austria.

**Chelvin Sng** | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

**Julian D. Stevens** | Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London, UK.

**Marie-Jose Tassignon** | Past Chief & Chair Department of Ophthalmology Antwerp University & University Hospital Antwerp, Belgium.

**Adnan Tufail** | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK. Professor, UCL Institute of Ophthalmology, London, UK.

**Tien Yin Wong** | Founding Head & Chair Professor, Tsinghua University, Beijing, China.

## ADVISORS

**Laurent Affias** | Senior VP, Head of Strategy, BD&L & Market Access, Alcon, USA.

**Christopher Brittain** | Global Head of Ophthalmology, Genentech, Burlingame, USA.

**Art Ciociola** | Vice President Global Head Regulatory Affairs GDD Ophthalmology, Devices, & Innovation, Novartis Pharma AG, Fort Worth, USA.

**Eugene de Juan** | Jean Kelly Stock Distinguished Chair, Ophthalmology, ForSight Labs & University of California, Menlo Park, California.

**Tom Dunlap** | Founder, Dunlap Ophthalmology Consulting, Board of Directors, Advisory Boards.

**Malvina Eydelman** | Director, Division of Ophthalmic & Ear, Nose & Throat Devices ODE/CDRH/FDA, USA.

**Reza Haque** | SVP & Global Head of OIC, Ophthalmic Innovation Center, Santen Santen Pharmaceutical.

**Paul Hallen** | Vice President & Global Head, Retina, Alcon, Texas, USA.

**Jim Mazzo** | Executive Chairman, Neurotech.

**Naveed Siddiqi** | Novo Ventures.

## ORGANISING COMMITTEE

**Keith Barton** | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK, Professor of Ophthalmology, UCL, UK.

**Kuldev Singh** | Professor of Ophthalmology & Director, Glaucoma Service, Stanford University Medical Center, Palo Alto, USA.

**Lea Pietrolongo** | Operational Director, Ophthalmology Futures Forums, UK.



**STAAR**  
SURGICAL